Overview

A Multi-center Study to Evaluate the Safety, Tolerability and Efficacy of TIN816 in Patients at Risk for Acute Kidney Injury Following Cardiac Surgery.

Status:
Not yet recruiting
Trial end date:
2024-05-13
Target enrollment:
Participant gender:
Summary
This is a randomized, multi-centric, placebo-controlled, participant and investigator-blinded study to evaluate the safety, tolerability and efficacy of TIN816 in adult patients at risk for acute kidney injury following cardiac surgery.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals